Amgevita Biosimilars and Biologic Medicines | About Us | Amgen


Amgen is an expert in the development of biologic medicines

Since 1980, Amgen has been at the forefront of biotechnology, helping invent the processes and tools that built the global biotechnology industry into the leading source of therapies for patients with few other options. Our expertise in biologics is now being applied into developing high quality, therapeutic biosimilars in order to deliver more value to both patients and healthcare systems.
Image showing the key benefits of Amgen's biosimilars.
Amgen biosimilars
Read more
  1. Tabernero J, et al. ESMO Open. 2016;1:e000142.
  2. World Health Organization. 11th General Programme of Work Executive Summary. Available at: Last accessed March 2019.
  3. Colombel JF, et al. Gastroenterology. 2017;152:351–61.

The information contained in this website is for European healthcare professionals only

I understand and confirm I am an EU healthcare professional
Read more >
I am not an EU healthcare professional
Read more >
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.